ストックスクリーナーアプリを入手
168.75
0.22%
0.235
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Neurocrine Biosciences stock hits all-time high at 169.62 USD - Investing.com
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Bull of the Day: Neurocrine Biosciences (NBIX) - Zacks Investment Research
Neurocrine Biosciences, Inc.(NasdaqGS: NBIX) dropped from Russell 1000 Dynamic Index - marketscreener.com
Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed? - Yahoo Finance
Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype - Yahoo Finance
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap? - simplywall.st
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now - Insider Monkey
Neurocrine Biosciences (NBIX): High Growth Stocks to Buy Right Now - Insider Monkey
Neurocrine Biosciences, Inc. Actuals & Estimates (NASDAQ:NBIX) - TradingView
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June - Investing.com UK
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June By Investing.com - Investing.com Australia
Price to earnings forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView
Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Price to sales forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Costco Stock And 2 Low Risk Picks Built For Volatile Markets - simplywall.st
Neurocrine Biosciences, Inc. Actuals & Estimates (DUS:NB3) - TradingView
NBIX Forecast — Price Target — Prediction for 2027 - TradingView
NB3 Forecast — Price Target — Prediction for 2027 - TradingView
5 High Growth Stocks to Buy Right Now - Insider Monkey
Neurocrine Biosciences Inc (NBIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Best Momentum Stocks to Buy for June 24th - Yahoo Finance Singapore
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework - ChartMill
Neurocrine Biosciences Inc (NBIX) Institutional Confidence - TradingKey
Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
New Strong Buy Stocks for June 24th - Yahoo Finance Singapore
Best Value Stocks to Buy for June 24th - Yahoo Finance Singapore
Neurocrine Biosciences (NBIX) Pe Ratio (TTM) - Zacks Investment Research
What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders - Sahm
Stifel reiterates Neurocrine Bio stock rating on Vykat potential By Investing.com - Investing.com Nigeria
Stifel reiterates Neurocrine Bio stock rating on Vykat potential - Investing.com
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 22.8% Potential Upside Amid Strong Growth Prospects - DirectorsTalk Interviews
Neurocrine Biosciences Inc (NBIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentals - ChartMill
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data - simplywall.st
Neurocrine Biosciences Inc (NBIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NBIX News | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurocrine Biosciences Inc (NBIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neurocrine Biosciences Inc (NBIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $246 - Moomoo
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate - ChartMill
Neurocrine presents long-term data on Prader-Willi drug By Investing.com - Investing.com South Africa
Neurocrine presents long-term data on Prader-Willi drug - Investing.com
Neurocrine presents case study on Crenessity for rare CAH subtype By Investing.com - Investing.com Australia
Neurocrine presents case study on Crenessity for rare CAH subtype - Investing.com
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY - StreetInsider
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 - The Grand Junction Daily Sentinel
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now? - Insider Monkey
1.01%
3.09%
大文字化:
|
ボリューム (24 時間):